- Home
- MDXG vs ZYME Comparison
MDXG vs ZYME Comparison
Compare MDXG & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXG
- ZYME
- Stock Information
- Founded
- MDXG 2006
- ZYME 2003
- Country
- MDXG United States
- ZYME United States
- Employees
- MDXG N/A
- ZYME N/A
- Industry
- MDXG Biotechnology: Pharmaceutical Preparations
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- MDXG Health Care
- ZYME Health Care
- Exchange
- MDXG Nasdaq
- ZYME Nasdaq
- Market Cap
- MDXG 1.0B
- ZYME 846.1M
- IPO Year
- MDXG N/A
- ZYME 2017
- Fundamental
- Price
- MDXG $6.43
- ZYME $11.43
- Analyst Decision
- MDXG Strong Buy
- ZYME Buy
- Analyst Count
- MDXG 2
- ZYME 7
- Target Price
- MDXG $12.50
- ZYME $19.50
- AVG Volume (30 Days)
- MDXG 852.6K
- ZYME 449.0K
- Earning Date
- MDXG 04-30-2025
- ZYME 05-08-2025
- Dividend Yield
- MDXG N/A
- ZYME N/A
- EPS Growth
- MDXG N/A
- ZYME N/A
- EPS
- MDXG 0.27
- ZYME N/A
- Revenue
- MDXG $352,375,000.00
- ZYME $93,384,000.00
- Revenue This Year
- MDXG $9.44
- ZYME $34.23
- Revenue Next Year
- MDXG $11.54
- ZYME $68.78
- P/E Ratio
- MDXG $23.82
- ZYME N/A
- Revenue Growth
- MDXG 5.34
- ZYME 85.05
- 52 Week Low
- MDXG $5.47
- ZYME $8.21
- 52 Week High
- MDXG $10.14
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- MDXG 38.95
- ZYME 45.92
- Support Level
- MDXG $6.46
- ZYME $11.46
- Resistance Level
- MDXG $6.90
- ZYME $11.81
- Average True Range (ATR)
- MDXG 0.23
- ZYME 0.59
- MACD
- MDXG -0.05
- ZYME -0.05
- Stochastic Oscillator
- MDXG 1.02
- ZYME 27.62
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.